BioTuesdays

Lexeo reports positive data from study of LX2020 in PKP2-ACM

Lexeo Therapeutics (NASDAQ: LXEO) has announced positive interim data from the ongoing HEROIC-PKP2 Phase 1/2 clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM).

According to Lexeo, across 10 participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions, as well as improvement of right ventricular function and patient-reported symptoms. The company is designing a pivotal study with NSVT as a primary surrogate endpoint to support potential accelerated approval, with the final study design, statistical analysis plan, and confirmatory strategy subject to future discussions with the FDA.

In a statement, R. Nolan Townsend, CEO of Lexeo, commented, “These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM. The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM. Our regulatory discussions also provide important clarity on the path forward, including the FDA’s openness to the use of NSVT as a primary endpoint in a planned pivotal study given the well-established association between NSVT and sustained, life-threatening arrhythmic risk.”

POWERED BY

Stay Ahead in Healthcare & Life Sciences